Home / People / Frances Lowe
Portrait ofFrances Denney

Frances Lowe

Senior Associate
Patent Attorney

Contact
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English

Frances is a Chartered UK and European Patent Attorney in the IP department, specialising in the Life Sciences space. Her practice focusses on patent prosecution, opposition and appeal work before the European Patent Office. Frances also has experience assisting on patent litigations, corporate due diligence, and freedom-to-operate matters. 

Frances has particular experience in the areas of CRISPR, RNAi, biomarkers, antibody technology, drug formulations and medical devices. More recently, Frances has also been involved in cross-sector technologies in the High-Tech and Life Sciences space, including digital biomarkers and AI-led screening techniques.

Prior to joining CMS, Frances worked for a start-up biotech company, helping to develop their R&D pipelines.

more less

Education

  • 2020 – CPA (Chartered Patent Attorney)
  • 2019 – EPA (European Patent Attorney)
  • 2016 – Certificate in IP Law – Queen Mary University of London, London
  • 2014 – MSc Drug Discovery and Pharma Management – UCL, London
  • 2013 – BSc Biochemistry – UCL, London
more less

Feed

18/05/2023
In View: The Unified Patents Court and the Unitary Patent – are you ready?
CMS are delighted to invite you to the next instalment of our Life Sciences & Healthcare update webinar, where experts from across the firm will discuss key industry topics impacting, innovating and disrupting...
18/01/2023
What is the significance of a clinical trial protocol as prior art at the...
The EPO Appeal Board has further refined their view on when prior art disclosures of clinical trial protocols are an issue for patentability of medical use claims. Decision T1806/18 In decision T1806/18...
14/09/2020
An EPO Case Law Round-Up: Added Matter
The EPO is well-known for its strict approach to assessing amendments under the added matter provision of Article 123 of the European Patent Convention. This often creates complex legal scenarios which...
25/06/2020
Supreme Court Decision - Regeneron v Kymab [2020] UKSC 27
Who knew a mouse could cause so much trouble? The Supreme Court handed down its judgment in the case of Regeneron v Kymab this week, ruling that the asserted claims of Regeneron’s European patent EP1360287...
19/05/2020
Not Patentable – The end of the line for plants and animals produced by...
The highest judicial authority at the EPO issued their opinion late last week in the controversial G3/19 (Pepper) case. Contrary to previous decisions in G2/12 and G2/13 (To­mato/Broc­coli), the Enlarged...
31/01/2020
A Short Guide: Priority Entitlement at the EPO
Article 87 EPC Priority right (1) Any person who has duly filed, in or for (a) any State party to the Paris Convention for the Protection of Industrial Property or (b) any Member of the World Trade Organization...
20/12/2019
‘Darunavir’ CJEU referral withdrawn - Article 3(a) of the SPC Regulation
At the end of September, we reported here on the publication of AG Hogan’s Opinion on the joint referrals from the German Bundes­pat­ent­gericht (case C-650/17) for Merck’s sitagliptin product and from...
17/12/2019
The rise of patent wars in Europe’s gene therapy space
The gene therapy industry is in an exciting phase of growth, undergoing significant M&A activity, product sales and new marketing authorisations that are being issued with increasing regularity globally...
19/09/2019
AI & patient compliance
This article looks at technology in the area of patient compliance, an area where AI is having a huge impact on the life sciences industry. Technologies facilitating patient compliance raise a host...
13/09/2019
SPC Double Whammy - Interpreting Article 3(a) of the SPC Regulation
Summary At the end of June, the CJEU heard the joint referrals from the German Bundes­pat­ent­gericht (case C-650/17) for Merck’s sitagliptin product and from the English Court of Appeal for Searle’s...
30/05/2019
EPO's strict approach to deciding if a composition can benefit from medical...
The EPO Technical Board of Appeal (TBA) reviewed the law around novelty of use, and determined that in the case of CardioPolymer, Inc.'s European patent application (EP07837908.8), the claimed chemical...
27/03/2019
Judgment on Abraxis C-443/17; 21st March 2019
The CJEU delivered its judgment last week on the case of Abraxis v Comptroller General of Patents concerning Supplementary Protection Certificates (SPCs) for new formulations of medicinal products. The...